All In Biotech

Drug Trial Radar · NCT02813551

ToRsemide for pOstpartum HYpertension

Torsemide for the Prevention of Persistent Postpartum Hypertension in Preeclamptic Women: A Randomized, Placebo-Control Trial

Last checked: Nov 20, 2026Latest source record: Apr 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Aug 2016

Primary completion

Jul 28, 2017

Study completion Sep 9, 2017

Sponsor

Lead sponsor
The University of Texas Health Science Center, HoustonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Currently there is no intervention to prevent persistent postpartum hypertension in preeclamptic women. Physiologically, the use of a pharmacokinetically predictable loop-diuretic is a reasonable intervention to increase elimination of extra fluid accumulated secondary to preeclampsia.The purpose of this study is to assess if Torsemide reduces the incidence of persistent postpartum hypertension in preeclamptic women.

Conditions

  • Preeclampsia

Interventions

  • TorsemideDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHgTime frame: 0-5 days after delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas Health Science Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.